首页 > 产品中心 > Recombinant Human BCMA Protein (ECD, rFc Tag), HPLC-verified
Recombinant Human BCMA Protein (ECD, rFc Tag), HPLC-verified
Cat No. BCMA-PH1204
库存:现货
Size
产品介绍
纯度
≥ 95 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC.
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
生物活性
1.Measured by its binding ability in a functional ELISA. Immobilized TNFRSF17 (Cat:10620-H15H) at 10 μg/mL (100 μL/well) can bind Fc-BAFF/Biotin (Cat:10056-H01H), the EC50 of Fc-BAFF/Biotin (Cat:10056-H01H) is 1.0-10.0 ng/mL.
2.Immobilized Recombinant Human TNFRSF17 / BCMA / CD269 Protein (rFc Tag) (Cat:10620-H15H) at 2μg/mL (100 μl/well) can bind Recombinant Human BLyS / TNFSF13B Protein (Fc & AVI Tag), Biotinylated (Cat: 10056-H42H-B), The EC50 is 1.5-6 ng/mL (QC tested).
3.Immobilized Anti-BCMA Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Recombinant Human TNFRSF17 / BCMA / CD269 Protein (rFc Tag) (Cat: 10620-H15H), the EC50 is 1.0-5.0 ng/mL (Routinely tested).
蛋白构建
A DNA sequence encoding the human TNFRSF17 (NP_001183.2) (Met1-Ala54) was expressed with the Fc region of rabbit IgG at the N-terminus.
Accession#
NP_001183.2
表达宿主
HEK293 Cells
种属
Human
预测 N 端
Ser
分子量
The recombinant human TNFRSF17 consists 303 amino acids and predicts a molecular mass of 33.3 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of human TNFRSF17 is approximately 33-44 kDa due to the glycosylation.
缓冲液
Lyophilized from sterile 20mM Tris, 500mM NaCl, pH8.0
Please
contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
运输方式
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
稳定性 & 储存条件
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
复溶
To find reconstitution info, click on 'COA' at the top of the page, enter the lot number and product size for the lot-specific COA.





Measured by its binding ability in a functional ELISA. Immobilized TNFRSF17 (Cat:10620-H15H) at 10 μg/mL (100 μL/well) can bind Fc-BAFF/Biotin (Cat:10056-H01H), the EC50 of Fc-BAFF/Biotin (Cat:10056-H01H) is 1.0-10.0 ng/mL.

Immobilized Recombinant Human TNFRSF17 / BCMA / CD269 Protein (rFc Tag) (Cat:10620-H15H) at 2μg/mL (100 μl/well) can bind Recombinant Human BLyS / TNFSF13B Protein (Fc & AVI Tag), Biotinylated (Cat: 10056-H42H-B), The EC50 is 1.5-6 ng/mL (QC tested).

Immobilized Anti-BCMA Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Recombinant Human TNFRSF17 / BCMA / CD269 Protein (rFc Tag) (Cat: 10620-H15H), the EC50 is 1.0-5.0 ng/mL (Routinely tested).

Recombinant Human BCMA Protein (ECD, rFc Tag), HPLC-verified: 别称              

BCM Protein, Human; BCMA Protein, Human; CD269 Protein, Human; TNFRSF13A Protein, Human

BCMA 背景信息                

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.
全称
tumor necrosis factor receptor superfamily member 17
参考文献
  • Novak AJ, et al. (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 103 (2): 689–94.

  • O'Connor BP, et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 199(1): 91-8.

  • Moser K, et al. (2006) Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol. 18(3): 265-70.


Copyright © 2021-2023 北京源沃生物科技有限公司 All Rights Reserved. 京ICP备2023011720号-1